Holders — by stockHoldings — by fund
Propel Bio Management, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001969764
$191.1M
disclosed book value
29
positions
16.2%
largest position share
Positions, as of 2026-06-30
top 29 of 29 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | PAGPPLAINS GP HOLDINGS LP-CL | 1.3M | $30.9M | 16.2% |
| 2 | ACHVACHIEVE LIFE SCIENCES INC | 4.0M | $26.3M | 13.8% |
| 3 | CORTCORCEPT THERAPEUTICS INC | 136,499 | $11.9M | 6.2% |
| 4 | PHATPHATHOM PHARMACEUTICALS I | 1.1M | $11.4M | 6% |
| 5 | DCTHDELCATH SYSTEMS INC | 871,460 | $11.0M | 5.7% |
| 6 | MISTMILESTONE PHARMACEUTICALS | 7.4M | $10.0M | 5.2% |
| 7 | CMPSCOMPASS PATHWAYS PLC | 573,086 | $8.1M | 4.2% |
| 8 | KYTXKYVERNA THERAPEUTICS INC | 883,198 | $7.9M | 4.1% |
| 9 | ARTVARTIVA BIOTHERAPEUTICS IN | 696,436 | $6.8M | 3.5% |
| 10 | ABEOABEONA THERAPEUTICS INC | 983,070 | $6.1M | 3.2% |
| 11 | AQSTAQUESTIVE THERAPEUTICS IN | 1.4M | $6.0M | 3.1% |
| 12 | PALIPALISADE BIO INC | 2.6M | $5.4M | 2.8% |
| 13 | IMUXIMMUNIC INC | 325,022 | $5.0M | 2.6% |
| 14 | IVAINVENTIVA SA - ADR | 1.3M | $4.8M | 2.5% |
| 15 | SABSSAB BIOTHERAPEUTICS INC | 1.1M | $4.2M | 2.2% |
| 16 | OBIOORCHESTRA BIOMED HOLDINGS | 896,701 | $3.9M | 2% |
| 17 | CLDXCELLDEX THERAPEUTICS INC | 103,695 | $3.9M | 2% |
| 18 | ZVRAZEVRA THERAPEUTICS INC | 253,544 | $3.6M | 1.9% |
| 19 | OCULOCULAR THERAPEUTIX INC | 357,966 | $3.5M | 1.8% |
| 20 | FDMT4D MOLECULAR THERAPEUTICS IN | 252,654 | $3.4M | 1.8% |
| 21 | OVIDOVID THERAPEUTICS INC | 1.1M | $3.0M | 1.6% |
| 22 | EYPTEYEPOINT INC | 191,745 | $2.7M | 1.4% |
| 23 | UPBUPSTREAM BIO INC | 350,389 | $2.4M | 1.3% |
| 24 | SCYXSCYNEXIS INC | 543,478 | $2.2M | 1.2% |
| 25 | SLNSILENCE THERAPEUTICS PLC | 191,733 | $2.1M | 1.1% |
| 26 | LONALEONABIO INC | 149,279 | $1.4M | 0.7% |
| 27 | MAZEMAZE THERAPEUTICS INC | 43,798 | $1.3M | 0.7% |
| 28 | CRVSCORVUS PHARMACEUTICALS INC | 70,380 | $1.1M | 0.6% |
| 29 | SGMTSAGIMET BIOSCIENCES INC-A | 125,878 | $973,037 | 0.5% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.